-
Mashup Score: 2
In the STOPDAPT-3 trial, an aspirin-free strategy after PCI did not reduce major bleeding event risk compared with dual antiplatelet therapy, with data also suggesting a signal for excess coronary events, a speaker reported. DAPT with a P2Y12 inhibitor on top of aspirin therapy is the established treatment to prevent ischemic CV events, in particular stent thrombosis, at least 1 month after PCI;
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Antiplatelet therapy is a cornerstone of secondary prevention of cardiovascular diseases (CVDs). However, current guidelines are based on data derived primarily from men, as women are generally underrepresented in trials. Consequently, there are insufficient and inconsistent data on the effect of an …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0IL-6 receptor antagonists, antiplatelets show high probability of benefit for COVID-19 - 1 year(s) ago
IL-6 receptor antagonists and antiplatelet agents improved chances for 6-month survival among patients with COVID-19, according to study results presented at Society of Critical Care Medicine’s Critical Care Congress and published in JAMA.“In our analysis of longer-term outcomes among critically ill patients with COVID-19 who participated in the Randomized Embedded Multifactorial
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1
Background: Evidence on the risk–benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent. Objective: To investigate the effect of renal function on the efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin treatment. Design: Post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial….
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2
Background: The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically-ill COVID-19 patients remains uncertain. Methods: COVID-PACT was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded endpoint adjudication …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Novel Factor XIa Inhibitors Show Promise for Bleeding Risk - 2 year(s) ago
Preventing ischemic events is a less clear benefit
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
August 5, 2022 — For people with coronary heart disease, beta-blockers can improve survival and quality of life, while aspirin and other antiplatelet medications can reduce the risk of a heart attack. But those protections could backfire during hot-weather events, a time when heart attacks are more likely. A new study found that, among people suffering non-fatal heart attacks associated with hot…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex percutaneous coronary intervention - 2 year(s) ago
This editorial refers to ‘Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT tri
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Antiplatelet therapy after percutaneous coronary intervention - 2 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: EuroInterventionCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
AbstractAims. Gene expression biosignatures may hold promise to individualize antiplatelet therapy in conjunction with current guidelines and risk scores. The A
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
The STOPDAPT-3 trial found that an #aspirin-free strategy following #PCI failed to reduce major #bleeding risk vs. dual #antiplatelet therapy. https://t.co/yaXZZAvQj5